First clinical trial of allergen-specific immunotherapy with digital Peak Flow technology
Healthcare technology and digitisation are playing an increasingly important role in our daily lives, leading to an improvement in the relationship between patients and healthcare professionals, as well as reducing healthcare costs. These advances also ensure better adherence to treatment and make it possible to monitor the health of patients. The use of technology in clinical research is becoming essential for patient analysis and follow-up.
Probelte Pharma is conducting the first clinical trial of allergen-specific immunotherapy with Peak Flow digital technology in Spain, in which the patient collects the data using 2 separate, user-friendly mobile applications: the “PROÁCAROS cartilla paciente” (patient chart) application to record their daily state of health, and the “PROÁCAROS Peak Flow” application to monitor their asthma. The trial aims to recruit 250 randomised patients, using 14 centres and involving 47 researchers.
Using these mobile applications to collect data is a useful tool because it benefits both the patient and the doctor by avoiding errors in data collection, improving adherence and providing a patient-friendly tool.
During the trial, the efficacy of the Beltavac® Polymerized PRO vaccine with a mixture of allergoids from the house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae will be evaluated.
The main objective will be to measure improvements in allergy symptoms, reductions in allergy medication use and, overall, patient quality of life and asthma control.
A key issue that will also be assessed during the trial is the impact of this vaccine on health economics.
Dust mite allergy affects more than 30% of the population in some regions of the country with warm and humid climates. The main symptom is rhinitis, which occurs mainly in the morning and at bedtime, and is often accompanied by asthma. This leads to medicine consumption that has an impact on the patient’s quality of life.
